Quantification and phenotyping of circulating tumor cells isolated with the GILUPI CellCollector® technology
(PresseBox) - GILUPI announces the release of a video article presenting an innovative approach for isolation of circulating tumor cells (CTCs) by the use of the GILUPI CellCollector® and their downstream phenotyping in combination with chromosomal rearrangement detection [1].
CTCs can often be found in the blood of cancer patients. They are a promising surrogate marker for disease progression and response to therapy. CTCs indicate tumor cell extravasation and are prerequisites for formation of metastasis. Detection and characterization of these rare cells could provide a powerful approach for early disease diagnosis as well as disease monitoring. The GILUPI CellCollector® offers medical personnel at any point-of-care with the unique opportunity to enrich these CTCs in vivo.
Fabbri and colleagues from Cancer Institute IRST of Meldola in Italy presented a method which combines immunofluorescence staining and DNA FISH analysis of in vivo isolated CTCs. They demonstrated the feasibility of this new approach by determination of tumor relevant markers (EpCAM expression and ALK chromosomal translocations) in a lung cancer cell line attached on the medical wire of GILUPI. This new concept will enhance prognostic value of CTCs and provides an innovative strategy for improving personalized cancer treatments.
[1] Fabbri et al. " Characterization of Tumor Cells Using a Medical Wire for Capturing Circulating Tumor Cells: A 3D Approach Based on Immunofluorescence and DNA FISH.? J Vis Exp. 2017 Dec 21;(130). doi: 10.3791/56936.
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.
Individual oncological targeted therapies will become more and more important in tomorrow?s personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly ?fishing? them in the patient?s bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.
For further information visit www.gilupi.com
Unternehmensinformation / Kurzprofil:
GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the in vivo isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.Individual oncological targeted therapies will become more and more important in tomorrow?s personalized medicine. The identification of the right drug for the specific patient is the upcoming challenge. To address this medical need, the application of the GILUPI CellCollector® enriches rare cells (circulating tumor cells - CTCs) by directly ?fishing? them in the patient?s bloodstream. By using special diagnostic analyses, these isolated cells can be characterized and/or analyzed at a molecular level.The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide that is CE approved.For further information visit www.gilupi.com
Datum: 13.07.2018 - 10:19 Uhr
Sprache: Deutsch
News-ID 578200
Anzahl Zeichen: 2571
contact information:
Town:
Potsdam
Kategorie:
Diese Pressemitteilung wurde bisher 320 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Quantification and phenotyping of circulating tumor cells isolated with the GILUPI CellCollector® technology"
steht unter der journalistisch-redaktionellen Verantwortung von
GILUPI GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
